Does the media prefer KURA or ELVN?

In the previous week, Enliven Therapeutics had 4 more articles in the media than Kura Oncology. MarketBeat recorded 6 mentions for Enliven Therapeutics and 2 mentions for Kura Oncology. Enliven Therapeutics' average media sentiment score of 0.56 beat Kura Oncology's score of 0.46 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IOVA or KURA?

In the previous week, Iovance Biotherapeutics had 11 more articles in the media than Kura Oncology. MarketBeat recorded 13 mentions for Iovance Biotherapeutics and 2 mentions for Kura Oncology. Iovance Biotherapeutics' average media sentiment score of 0.68 beat Kura Oncology's score of 0.46 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, TLX or KURA?

Telix Pharmaceuticals has higher revenue and earnings than Kura Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.76 -$7.12M N/A N/A Kura Oncology $67.48M 14.55 -$278.67M -$3.37 N/A

Does the media prefer TLX or KURA?

In the previous week, Telix Pharmaceuticals had 27 more articles in the media than Kura Oncology. MarketBeat recorded 29 mentions for Telix Pharmaceuticals and 2 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.46 beat Telix Pharmaceuticals' score of 0.31 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 5 Very Positive mention(s) 11 Positive mention(s) 6 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KURA or AMLX?

In the previous week, Kura Oncology had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 2 mentions for Kura Oncology and 1 mentions for Amylyx Pharmaceuticals. Kura Oncology's average media sentiment score of 0.46 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amylyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor VKTX or KURA?

In the previous week, Viking Therapeutics had 32 more articles in the media than Kura Oncology. MarketBeat recorded 34 mentions for Viking Therapeutics and 2 mentions for Kura Oncology. Viking Therapeutics' average media sentiment score of 0.46 beat Kura Oncology's score of 0.46 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 14 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kura Oncology (KURA) Competitors

$11.04 -0.69 (-5.88%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$10.94 -0.10 (-0.95%)

As of 06:06 AM Eastern

Compare

KURA vs. ELVN, IOVA, TLX, AMLX, and VKTX

Should you buy Kura Oncology stock or one of its competitors? Kura Oncology's main competitors and comparable companies include Enliven Therapeutics (ELVN), Iovance Biotherapeutics (IOVA), Telix Pharmaceuticals (TLX), Amylyx Pharmaceuticals (AMLX), and Viking Therapeutics (VKTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kura Oncology compare to Enliven Therapeutics?

Kura Oncology (NASDAQ:KURA) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Enliven Therapeutics has lower revenue, but higher earnings than Kura Oncology. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	14.55	-$278.67M	-$3.37	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Enliven Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Enliven Therapeutics' return on equity of -18.55% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Enliven Therapeutics	N/A	-18.55%	-18.09%

95.1% of Enliven Therapeutics shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Enliven Therapeutics had 4 more articles in the media than Kura Oncology. MarketBeat recorded 6 mentions for Enliven Therapeutics and 2 mentions for Kura Oncology. Enliven Therapeutics' average media sentiment score of 0.56 beat Kura Oncology's score of 0.46 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enliven Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kura Oncology presently has a consensus target price of $25.40, suggesting a potential upside of 130.07%. Enliven Therapeutics has a consensus target price of $75.00, suggesting a potential upside of 62.73%. Given Kura Oncology's higher possible upside, analysts clearly believe Kura Oncology is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Kura Oncology has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

Summary

Enliven Therapeutics beats Kura Oncology on 9 of the 15 factors compared between the two stocks.

How does Kura Oncology compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Kura Oncology (NASDAQ:KURA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 7.6% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Iovance Biotherapeutics presently has a consensus price target of $9.11, indicating a potential downside of 10.59%. Kura Oncology has a consensus price target of $25.40, indicating a potential upside of 130.07%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Kura Oncology is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Iovance Biotherapeutics has a net margin of -89.11% compared to Kura Oncology's net margin of -384.30%. Iovance Biotherapeutics' return on equity of -40.51% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Kura Oncology	-384.30%	-207.18%	-45.17%

In the previous week, Iovance Biotherapeutics had 11 more articles in the media than Kura Oncology. MarketBeat recorded 13 mentions for Iovance Biotherapeutics and 2 mentions for Kura Oncology. Iovance Biotherapeutics' average media sentiment score of 0.68 beat Kura Oncology's score of 0.46 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Iovance Biotherapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

Kura Oncology has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	17.52	-$390.98M	-$0.73	N/A
Kura Oncology	$67.48M	14.55	-$278.67M	-$3.37	N/A

Summary

Iovance Biotherapeutics beats Kura Oncology on 11 of the 16 factors compared between the two stocks.

How does Kura Oncology compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Kura Oncology (NASDAQ:KURA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

In the previous week, Telix Pharmaceuticals had 27 more articles in the media than Kura Oncology. MarketBeat recorded 29 mentions for Telix Pharmaceuticals and 2 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.46 beat Telix Pharmaceuticals' score of 0.31 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	5 Very Positive mention(s)	11 Positive mention(s)	6 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Telix Pharmaceuticals' return on equity of 0.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Kura Oncology	-384.30%	-207.18%	-45.17%

Telix Pharmaceuticals presently has a consensus target price of $20.50, indicating a potential upside of 81.90%. Kura Oncology has a consensus target price of $25.40, indicating a potential upside of 130.07%. Given Kura Oncology's higher probable upside, analysts plainly believe Kura Oncology is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Telix Pharmaceuticals has higher revenue and earnings than Kura Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.76	-$7.12M	N/A	N/A
Kura Oncology	$67.48M	14.55	-$278.67M	-$3.37	N/A

Telix Pharmaceuticals has a beta of -0.17, suggesting that its stock price is 117% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Summary

Telix Pharmaceuticals beats Kura Oncology on 8 of the 13 factors compared between the two stocks.

How does Kura Oncology compare to Amylyx Pharmaceuticals?

Kura Oncology (NASDAQ:KURA) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Amylyx Pharmaceuticals has higher revenue and earnings than Kura Oncology. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	14.55	-$278.67M	-$3.37	N/A
Amylyx Pharmaceuticals	$87.37M	39.02	-$144.74M	-$1.43	N/A

Kura Oncology has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market.

In the previous week, Kura Oncology had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 2 mentions for Kura Oncology and 1 mentions for Amylyx Pharmaceuticals. Kura Oncology's average media sentiment score of 0.46 beat Amylyx Pharmaceuticals' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Amylyx Pharmaceuticals' return on equity of -52.92% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Kura Oncology currently has a consensus target price of $25.40, indicating a potential upside of 130.07%. Amylyx Pharmaceuticals has a consensus target price of $38.86, indicating a potential upside of 26.98%. Given Kura Oncology's higher possible upside, equities research analysts clearly believe Kura Oncology is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Amylyx Pharmaceuticals beats Kura Oncology on 10 of the 17 factors compared between the two stocks.

How does Kura Oncology compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Kura Oncology (NASDAQ:KURA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

In the previous week, Viking Therapeutics had 32 more articles in the media than Kura Oncology. MarketBeat recorded 34 mentions for Viking Therapeutics and 2 mentions for Kura Oncology. Viking Therapeutics' average media sentiment score of 0.46 beat Kura Oncology's score of 0.46 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	14 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viking Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Viking Therapeutics' return on equity of -94.56% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Kura Oncology	-384.30%	-207.18%	-45.17%

Kura Oncology has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Kura Oncology	$67.48M	14.55	-$278.67M	-$3.37	N/A

Viking Therapeutics currently has a consensus price target of $99.67, suggesting a potential upside of 139.30%. Kura Oncology has a consensus price target of $25.40, suggesting a potential upside of 130.07%. Given Viking Therapeutics' higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

76.0% of Viking Therapeutics shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Viking Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

Summary

Viking Therapeutics beats Kura Oncology on 8 of the 15 factors compared between the two stocks.

Get Kura Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KURA vs. The Competition

Export

Metric	Kura Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.04B	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-3.28	13.88	274.08	25.69
Price / Sales	14.55	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	5.52	15.40	10.47	6.32
Net Income	-$278.67M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-5.80%	-1.70%	-0.67%	0.17%
1 Month Performance	-10.97%	-6.17%	-3.17%	-3.27%
1 Year Performance	31.74%	30.67%	15.14%	5.58%

Kura Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KURA Kura Oncology	3.3774 of 5 stars	$11.04 -5.9%	$25.40 +130.1%	+34.0%	$1.04B	$67.48M	N/A	260
ELVN Enliven Therapeutics	2.286 of 5 stars	$54.43 +0.2%	$75.00 +37.8%	+140.2%	$3.98B	N/A	N/A	67	Positive News Insider Trade
IOVA Iovance Biotherapeutics	1.7139 of 5 stars	$9.26 +7.7%	$8.89 -4.0%	+392.3%	$3.90B	$263.50M	N/A	975
TLX Telix Pharmaceuticals	4.6192 of 5 stars	$11.78 +4.3%	$20.40 +73.2%	+3.1%	$3.84B	$890.79M	N/A	1,184	Trending News Analyst Upgrade Gap Up High Trading Volume
AMLX Amylyx Pharmaceuticals	3.3342 of 5 stars	$33.64 +6.4%	$36.50 +8.5%	+127.0%	$3.75B	N/A	N/A	136

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KURA) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kura Oncology (KURA) Competitors

KURA vs. ELVN, IOVA, TLX, AMLX, and VKTX

How does Kura Oncology compare to Enliven Therapeutics?

Summary

How does Kura Oncology compare to Iovance Biotherapeutics?

Summary

How does Kura Oncology compare to Telix Pharmaceuticals?

Summary

How does Kura Oncology compare to Amylyx Pharmaceuticals?

Summary

How does Kura Oncology compare to Viking Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kura Oncology (KURA) Competitors

KURA vs. ELVN, IOVA, TLX, AMLX, and VKTX

How does Kura Oncology compare to Enliven Therapeutics?

Which has higher valuation and earnings, KURA or ELVN?

Is KURA or ELVN more profitable?

Do institutionals and insiders hold more shares of KURA or ELVN?

Does the media prefer KURA or ELVN?

Do analysts prefer KURA or ELVN?

Which has more volatility & risk, KURA or ELVN?

Summary

How does Kura Oncology compare to Iovance Biotherapeutics?

Do institutionals and insiders believe in IOVA or KURA?

Do analysts rate IOVA or KURA?

Is IOVA or KURA more profitable?

Does the media refer more to IOVA or KURA?

Which has more volatility & risk, IOVA or KURA?

Which has preferable valuation and earnings, IOVA or KURA?

Summary

How does Kura Oncology compare to Telix Pharmaceuticals?

Does the media prefer TLX or KURA?

Is TLX or KURA more profitable?

Do analysts prefer TLX or KURA?

Which has stronger valuation & earnings, TLX or KURA?

Which has more risk & volatility, TLX or KURA?

Summary

How does Kura Oncology compare to Amylyx Pharmaceuticals?

Which has better valuation and earnings, KURA or AMLX?

Which has more risk & volatility, KURA or AMLX?

Does the media favor KURA or AMLX?

Is KURA or AMLX more profitable?

Do analysts rate KURA or AMLX?

Do institutionals & insiders believe in KURA or AMLX?

Summary

How does Kura Oncology compare to Viking Therapeutics?

Does the media favor VKTX or KURA?

Is VKTX or KURA more profitable?

Which has preferable earnings & valuation, VKTX or KURA?

Do analysts rate VKTX or KURA?

Do institutionals & insiders hold more shares of VKTX or KURA?

Which has more volatility and risk, VKTX or KURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools